Immunomodulatory nanodiamond aggregate-based platform for the treatment of rheumatoid arthritis

Amanda Pentecost, Min Ju Kim, Sangmin Jeon, Young Ji Ko, Ick Chan Kwon, Yury Gogotsi, Kwangmeyung Kim, Kara L. Spiller

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We previously demonstrated that octadecylamine-functionalized nanodiamond (ND-ODA) and dexamethasone (Dex)-adsorbed ND-ODA (ND-ODA-Dex) promoted anti-inflammatory and pro-regenerative behavior in human macrophages in vitro. In this study, we performed a pilot study to investigate if these immunomodulatory effects translate when used as a treatment for rheumatoid arthritis in mice. Following local injection in limbs of mice with collagen type II-induced arthritis, microcomputed tomography showed that mice treated with a low dose of ND-ODA and ND-ODA-Dex did not experience bone loss to the levels observed in non-treated arthritic controls. A low dose of ND-ODA and ND-ODA-Dex also reduced macrophage infiltration and expression of pro-inflammatory mediators iNOS and tumor necrosis factor-a compared to the arthritic control, while a high dose of ND-ODA increased expression of these markers. Overall, these results suggest that ND-ODA may be useful as an inherently immunomodulatory platform, and support the need for an in-depth study, especially with respect to the effects of dose.

Original languageEnglish
Pages (from-to)163-174
Number of pages12
JournalRegenerative Biomaterials
Volume6
Issue number3
DOIs
Publication statusPublished - 2019 Jun 1
Externally publishedYes

    Fingerprint

Keywords

  • Biomaterial-cell interaction
  • Drug delivery
  • Nanobiomaterials

ASJC Scopus subject areas

  • Biomaterials

Cite this

Pentecost, A., Kim, M. J., Jeon, S., Ko, Y. J., Kwon, I. C., Gogotsi, Y., Kim, K., & Spiller, K. L. (2019). Immunomodulatory nanodiamond aggregate-based platform for the treatment of rheumatoid arthritis. Regenerative Biomaterials, 6(3), 163-174. https://doi.org/10.1093/rb/rbz012